Boston-based Dana-Farber Cancer Institute recorded an operating income of $61.2 million (3% operating margin) in the first half of fiscal 2026, compared to an operating income of $61.5 million (3.2% margin) during the same period last year.
Dana-Farber reported total operating revenue of $2.1 billion for the six months ended March 31, up from $1.9 billion during the same period last year. Net patient service revenue was $1.6 billion, up from $1.5 billion. The increase in net patient service revenue was attributed to a growth in patient volume and pharmacy revenue. Clinic visits grew 3.2% year over year and infusion visits grew 6.1%.
Total operating expenses were $2 billion in H1 2026, up from $1.8 billion during the same period last year. Total patient service expenses were $1.4 billion, up from $1.2 billion. Dana-Farber said this increase was primarily driven by higher patient volumes, compensation-related expenses and rising pharmaceutical costs. Total research expenses were $322.9 million, down from $327 million. Total general and administrative expenses were $324.2 million, up from $323.7 million.
Dana-Farber recorded a net income of $108.2 million in the first half of 2026, up from $104.1 million during the same period last year.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
